Browsing Tag
Pulmonary Arterial Hypertension
4 posts
Why Wall Street and clinicians may be watching IKT-001 more closely after the Phase 3 launch
Could IKT-001 change the PAH treatment landscape? Read why Inhibikase Therapeutics’ Phase 3 launch could become a major 2026 biotech catalyst.
GSK bets on activin signalling with $950m 35Pharma acquisition
Discover why GSK plc is acquiring 35Pharma Inc. for $950 million and what HS235 could mean for the future of pulmonary hypertension treatment.
Keros Therapeutics adjusts TROPOS trial of cibotercept amid safety concerns
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced significant changes to its Phase 2 TROPOS trial evaluating…
Tentative approval granted to Alembic Pharmaceuticals for pulmonary hypertension treatment by FDA
Alembic Pharmaceuticals Limited has achieved a significant milestone by securing tentative approval from the US Food & Drug…